Associazione Nazionale Medici Cardiologi Ospedalieri

CONGRESS ABSTRACT

CONGRESS ABSTRACT

Categorie
Dapagliflozin use in HFrEF patients: a single centre comparison between real-life and DAPA-HF data
Anno:
2023
Background: Practice guidelines recommend Sodium-glucose co-transporter-2 inhibitors (SGLT2-i) for patients with heart failure with reduced ejection fraction (HFrEF). Our study aimed to describe our population of patients with indications for Dapagliflozin, to compare it with the DAPA-HF trial population and assess the possible prognostic evolution. Methods: We retrospectively analysed…
EXTRINSIC COMPRESSION OF THE RIGHT VENTRICLE CAUSING ISOLATED RIGHT HEART FAILURE
Anno:
2023
Isolated right heart failure (RHF) can be caused by right ventricular (RV) compression, mainly described in severe cases of pectus excavatum. Mediastinal masses can determine an extrinsic compression of the RV. A 62-year-old retired agricultural inspector from Sicily presented in our clinic with worsening signs of RHF. His medical…
ESPERIENZA DI TERAPIA CON SACUBITRIL/VALSARTAN (S/V) NELLO SCOMPENSO CARDIACO A FRAZIONE D’EIEZIONE RIDOTTA (HFrEF) IN PAZIENTI AFFETTI DA CARDIOPATIA AMILOIDE DA TRANSTIRETINA WLD TYPE (ATTRwt): UNA STRADA DA PERCORRERE ?
Anno:
2023
INTRODUZIONE: ATTRwt è gravata da elevata morbilità, con sopravvivenza media dalla diagnosi di 43 mesi e mortalità del 50% a 4 anni. I pazienti (pz) esordiscono tipicamente con scompenso cardiaco a frazione d’eiezione preservata (HFpEF), alcuni evolvono rapidamente verso HFrEF. ATTRwt è una sfida dal punto di vista terapeutico. Tafamidis è l’unico agente eziologico disponibile in Italia e la…
Different kinetics of NT-proBNP and sST2 highlight different therapeutic pathways of sacubitril/valsartan
Anno:
2023
Background: N-terminal pro-B-type natriuretic peptide (NT-proBNP) and soluble interleukin 1 receptor-like 1 ST2 (sST2) are biomarkers used to grade heart failure with reduced ejection fraction (HFrEF) severity. The first is associated with the patient’s hemodynamic status, while the second is indicative of the inflammatory component and of myocardial fibrosis…
ASSOCIATION BETWEEN AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE AND A SEVERE DILATED CARDIOMYOPATHY: A CASE REPORT
Anno:
2023
Autosomal dominant polycystic kidney disease (ADPKD) is caused by mutations in PKD1 and PKD2 genes, encoding polycystin 1 and 2. We report the case of a 51-year-old woman with arterial hypertension and stage V chronic kidney disease from polycystic kidney disease, without a significant family health history. She was…
CARDIOMIOPATIA PERIPARTUM: COME RICONOSCERLA E COME TRATTARLA
Anno:
2023
Introduzione: La cardiomiopatia peripartum è caratterizzata da disfunzione sistolica del LV in assenza di altra patologia cardiaca esistente. Esordisce con segni clinici dello scompenso cardiaco acuto, con aritmie ventricolari o arresto cardiaco nelle ultime fasi della gravidanza fino ai 5-6 mesi dopo il parto. Il LV può essere non…
Short-term effects of Dapagliflozin on cardiac biomarkers, fluid retention, renal and pulmonary function in HFrEF patients: not as good as expected
Anno:
2023
Background: Sodium-glucose co-transporter-2 inhibitors (SGLT2-i) are currently a standard therapy for patients with heart failure with reduced ejection fraction (HFrEF). Still, their potential benefits on biomarkers, respiratory function parameters and fluid retention have not been extensively studied. Bioimpedance vector analysis (BIVA) has emerged as a new tool capable of…